Effectiveness of the HeartHab Application on Exercise Capacity in Patients With Coronary Artery Disease

Hasselt University

Status: Completed

Conditions: Coronary Artery Disease

Treatments: Other: Use of HeartHab application followed by usual care; Other: Usual care followed by the use of HeartHab application

Study type: Interventional

Funder types: Other

Identifiers

NCT03102671

HeartHab-002

Details and patient eligibility

About

The recurrence of major cardiac events after infarction is very high, in some populations up to 20% in the first year. Optimal secondary prevention as organized in cardiac rehabilitation centers is effective in reducing both morbidity and mortality. However, many studies have shown that the participation and adherence rate in CR-programs is low in most European countries. Therefore, novel ways of delivering secondary prevention using information technology and self-monitoring are being explored. Hence, this study will investigate the effectiveness of a mobile, patient tailored, app based multidisciplinary telerehabilitation program (HeartHab app) in improving exercise capacity, lifestyle and risk factors in patients with coronary artery disease in a post-rehabilitation setting.

Full description

Study design and population This study is a prospective double-arm, non-pragmatic, cross-over, randomized controlled trial. Approximately 30 subjects will be selected retrospectively from the cardiology database of the Jessa Hospital Hasselt. Subjects who do not violate any of the predefined exclusion criteria and have provided informed consent will be randomly assigned in a 1:1 ratio to the treatment strategies (AB sequence or BA sequence).

After two months, each individual will be switched to the other treatment strategy.

Measurements At baseline, after two months (+14 days) and after four months (+14 days), a clinical assessment, medical history, current medication therapy, fasting blood sample, maximal cardiopulmonary exercise test, pulmonary function and three completed questionnaires (HeartQol, IPAQ and EQ-5D) will be collected of all patients. A fourth questionnaire will be completed by all the patients, focusing on the usability of the HeartHab-application.

Statistical analysis Data analysis will be performed using SPSS version 22 (SPSS Inc, Chicago, IL, USA) according to the intention-to-treat principle by assigned treatment group. Nonparametric alternatives will be used for parametric statistics in case assumptions for the latter are violated. The Shapiro-Wilk test will be used to assess normality. Paired t tests (parametric) or Wilcoxon signed rank tests (nonparametric) will be used for within-group analysis; independent t tests (parametric) or Mann-Whitney U tests (nonparametric) for between-group analysis. Chi-square tests will be used in case of categorical variables; Fisher's exact tests will be used when expected frequencies are small. The significance level for tests is 2-sided α=.05.

The cost-effectiveness evaluation will be conducted from a society and patient perspective, taking into account both intervention and health care resource costs. As the majority of patients will be retired, productivity losses due to illness-related absence from the workplace will not be taken into account.

Health care costs will be the aggregated costs of hospital admissions for cardiovascular reasons and also specialist visits and associated diagnostics. The cardiovascular rehospitalizations' related costs will be derived from invoices retrieved from the recruiting hospitals' financial departments. INAMI/RIZIV's nomenclature-based tariffs will define specialist visits and diagnostics denominations.

Quality adjusted life years (QALYs) will be used as a generic measure of effectiveness. Estimates of QALYs will be derived from the EQ-5D questionnaire. The EQ-5D scores will be converted to utility scores. The utility estimates will be converted to adjusted mean QALYs by calculating the area under the curve (AUC) utility estimates for all time intervals for each patient, weighted by the length of follow-up at that time interval. The change from baseline utility (adjusted differential incremental QALYs) will then be calculated, using the multiple regression model to control for baseline utility differences.

The incremental cost-effectiveness ratio (ICER) will be calculated (ICER¼(Cost intervention group - Cost control group)/(Effectiveness intervention group - Effectiveness control group)) to compare costs and outcomes (effectiveness) across both treatment groups. The incremental cost will be determined by the difference in total average cost per patient between the intervention group and control group. The incremental effectiveness will be estimated by the adjusted differential incremental QALYs.

Enrollment: 30 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• History of coronary artery disease with or without intervention (PCI/CABG/conservative)
• History of a cardiac rehabilitation (CR) program
• Clinically stable without inducible ischemia or high risk ventricular arrhythmia, confirmed by the last available maximal ergospirometry test
• Age ≥18 years
• Willing and physically able to follow an app based telerehabilitation program and other study procedures in a four months follow-up period
• Evidence of a personally signed and dated informed consent, indicating that the subject (or legally-recognised representative) has been informed of all pertinent aspects of the study
• Possession of and/or able to use an Android smartphone
• Dutch speaking and understanding

Exclusion criteria

• Recent PCI or CABG procedure, and still included in a CR program
• Orthopedic, neurologic or any other pathologic condition which makes the patient physically unable to follow an app based telerehabilitation program
• Planned interventional procedure or surgery in the next four months
• Pregnant females
• Present cardiovascular complaints
• Participation in other cardiac rehabilitation program trials, focusing on exercise outcome
• Any condition which in the opinion of the investigator would make it unsafe or unsuitable for the patient to participate in this study or a life expectancy of less than 4 months based on investigators judgement

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

30 participants in 2 patient groups

AB sequence

Experimental group

Description:

Usual care followed by use of HeartHab application: Treatment A comprises the usual care (i.e. one information session on the importance of medication adherence, risk factor control and healthy lifestyle), followed by telemonitoring during treatment B. The tele-intervention will consist of two months telerehabilitation and telecoaching concerning physical activity, healthy lifestyle and medication adherence.

Treatment:

Other: Usual care followed by the use of HeartHab application

BA sequence

Experimental group

Description:

Use of HeartHab application followed by usual care: patients will be followed by telemonitoring during treatment B. The tele-intervention will consist of two months telerehabilitation and telecoaching concerning physical activity, healthy lifestyle and medication adherence, followed by treatment A comprises the usual care (i.e. one information session on the importance of medication adherence, risk factor control and healthy lifestyle)

Treatment:

Other: Use of HeartHab application followed by usual care